And the scale hasn't moved
S, Polycaprolactone nanoparticles as promising candidates for nanocarriers in novel nanomedicines
What to Expect Semaglutide is ideal for individuals with a body mass index (BMI) of 30 or greater or for adults with a BMI of 27 who also have at least one weight-related complication such as hypertension, insulin resistance, high cholesterol, or heart disease
Critics argued this was both medically suboptimal (small-molecule drugs are often more convenient for patients, more orally bioavailable, and more amenable to global manufacturing) and economically distorting (it adds complexity and cost to the therapy development process without clinical justification)
Crafted for Quality The Bobs Best Promise
High gastrointestinal discontinuation rates exceeding 50% across all doses, combined with liver safety signals in early studies, ultimately led Pfizer to discontinue danugliprons development in April 2025